Study on Minicell Generation of Lactobacillus acidophilus VTCC-B-871 for Drug Delivery

The practice of developing molecularly targeted drugs to achieve a higher degree of cancer therapy and antibiotic resistance is indispensable. Recently, bacterially derived 400nm sized minicells was reported on the ability of encapsulation with chemotherapeutic drugs. Lactobacillus acidophilus strain participated in the anti-cancer effects and performed the high-level specificity for cancer cell lines. Here we discuss minicells generation of Lactobacillus acidophilus VTCC-B-871 for drug delivery. The present work was the first report on that L. acidophilus VTCC-B-871 formed minicells with highly significant ratio (25 %) in modified MRS broth with fructose 10 g/l carbon source concentration. The minicells were packaged with Paclitaxel (10 µg/ml) and Cephalosporin (10 µg/ml) at different times of incubation (10, 15, 24 hours) at 37°C. As a result, minicells could completely absorbed in 10 hours by detecting the extraction after drug packaged minicells on antimicrobial activities on S. aureus ATCC 25923, E. coli ATCC 9637, Salmonella typhi ATCC 19430, C. albicans ATCC 14053, P . aeruginosa ATCC 27853.